Home › Trials › Stomach & bowel

Kidney cancer

A Study to Compare Gastrointestinal Adverse Events of Two Cabozantinib Tablet Types in Adult patients With Advanced or Metastatic Kidney Cancer

Who can joinWomen

AgeAsk the trial team

Kind of studyPhase 2: does it work?

What it testsA medicine

The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.

Contact hospital

The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.

CBCC Global ResearchIndiaDirections ↗

Registry summary (technical)

A Phase 2/3 Randomized, Parallel, Multicenter, Safety Study to Evaluate Gastrointestinal Adverse Events of Azurity Cabozantinib Tablets vs. CABOMETYXÂ® (cabozantinib) Tablets as a Single-Agent in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma - NIL

Sponsor: Azurity Pharmaceuticals, Inc.
CTRI/2025/11/097766 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 22 Jun 2026 · read by us 5 Nov 2026

Need help reaching the trial team? Write to us.

Tell us the city, the type of cancer and the trial number if you have one. We reply in simple words within 3 working days.

ट्रायल टीम से जुड़ने में मदद चाहिए? हमें ईमेल करें।

ట్రయల్ టీమ్‌ను సంప్రదించడానికి సహాయం కావాలా? మాకు ఈమెయిల్ చేయండి.

சோதனைக் குழுவை தொடர்பு கொள்ள உதவி வேண்டுமா? எங்களுக்கு மின்னஞ்சல் செய்யுங்கள்.